Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.
Site Search
Study reaffirms the Foundation's commitment to advance solutions to the growing challenge of antibiotic resistance and evaluate the use of phage to treat infections for people with CF
The Cystic Fibrosis Foundation announced a new set of research agreements to drive progress on its Path to a Cure. The nine awards will advance a variety of tools and strategies to accelerate treatments for the underlying cause of cystic fibrosis for all people with CF, regardless of their mutations.
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $2.17 million to Beyond Air® to support the development of a portable inhaled nitric oxide treatment for nontuberculous mycobacteria, difficult-to-treat bacteria that infect the lungs of people with cystic fibrosis.
Dr. Steven Rowe will support mission to cure cystic fibrosis by leading the Foundation’s research strategy, focusing on genetic therapies
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. Join the team that’s adding tomorrows.
Learn more about our Board and Officer Conflict of Interest Policy.
Learn more about the Cystic Fibrosis Foundation’s Code of Ethics.
Breadth of expertise in business, philanthropy, community engagement, and venture capital to help advance Foundation’s mission